Last $4.89 USD
Change Today 0.00 / 0.00%
Volume 245.4K
CYTK On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

cytokinetics inc (CYTK) Snapshot

Open
$4.88
Previous Close
$4.89
Day High
$4.95
Day Low
$4.75
52 Week High
04/24/14 - $13.26
52 Week Low
10/13/14 - $3.05
Market Cap
179.0M
Average Volume 10 Days
225.8K
EPS TTM
$-0.45
Shares Outstanding
36.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTOKINETICS INC (CYTK)

cytokinetics inc (CYTK) Related Businessweek News

No Related Businessweek News Found

cytokinetics inc (CYTK) Details

Cytokinetics, Incorporated, a clinical stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the treatment of heart failure. The company holds a license to develop and commercialize omecamtiv mecarbil and related compounds worldwide. It develops tirasemtiv, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the United States Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics, Incorporated has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to develop a skeletal muscle activator structurally distinct from tirasemtiv, for non-neuromuscular indications. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.

85 Employees
Last Reported Date: 03/7/14
Founded in 1997

cytokinetics inc (CYTK) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $555.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $391.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $388.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $347.5K
Senior Vice President of Human Resources
Total Annual Compensation: $278.0K
Compensation as of Fiscal Year 2013.

cytokinetics inc (CYTK) Key Developments

Cytokinetics, Incorporated Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:00 PM

Cytokinetics, Incorporated Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Robert I. Blum, Chief Executive Officer, President, Director and Chief Executive of the Biopharmaceutical Concern.

Cytokinetics, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

Cytokinetics, Incorporated reported earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s net loss was $6.0 million, or $0.16 per basic and diluted share. This is compared to a net loss for the same period in 2013, of $12.6 million, or $0.43 per basic and diluted share. Revenues were $9.4 million, compared to $4.5 million during the same period in 2013. Revenues for the third quarter of 2014 included $4.8 million of research and development revenues and $2.7 million of license revenues from the company's collaboration with Astellas, and $1.9 million of research and development revenues From the company's collaboration with Amgen. Operating loss was $5.998 million against $12.611 million a year ago. For the nine months, the company’s revenues were $25.2 million, compared to $6.3 million for the same period in 2013. Revenues for the first nine months of 2014 were primarily comprised of $14.1 million of research and development revenues and $7.6 million of license revenues From the company's collaboration with Astellas, and $3.4 million of research and development revenues From the company's collaboration with Amgen. Net loss was $23.1 million, or $0.65 per basic and diluted share, compared to a net loss of $40.2 million, or $1.52 per basic and diluted share, for the same period in 2013. Operating loss was $23.175 million against $40.326 million a year ago. The company provided updated financial guidance for 2014: cash revenues are expected to be approximately $19 to $21 million, cash R&D expenses are expected to be in the range of $45 to $48 million, and cash G&A expenses are expected to be in the range of $15 to $17 million. This financial guidance is on a cash basis and does not include the deferral of approximately $11 million in revenue associated with the Astellas and Amgen collaborations and an estimated $3.6 million in non-cash related operating expenses primarily related to stock compensation expense.

Cytokinetics, Incorporated Provides Update on Omecamtiv Mecarbil

Cytokinetics, Incorporated provided an update relating to omecamtiv mecarbil, the company’s drug candidate from its cardiac muscle contractility program. The company announced that COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) has enrolled over 275 patients towards the objective of 450 patients in the ongoing expansion phase of the trial. In addition, over 70 patients have completed the 20 weeks of dosing in the expansion phase of COSMIC-HF. Recently, the Data Monitoring Committee reviewed data from COSMIC-HF and recommended that the trial continue without any changes to the protocol. Patient enrollment in COSMIC-HF is expected to conclude by the end of 2014. The company also announced that CY 1211, a phase I study comparing the tolerability and pharmacokinetics of omecamtiv mecarbil between Japanese and Caucasian healthy volunteers, is complete and indicates no clinically meaningful differences between the two groups studied. Data from CY 1211 are expected to inform plans for the development of omecamtiv mecarbil in Japan and the inclusion of Japan in potential global Phase III program activities. COSMIC-HF is a double-blind, randomized, placebo-controlled, multicenter, dose escalation study designed to assess the pharmacokinetics and tolerability of three oral modified-release formulations of omecamtiv mecarbil in patients with heart failure and left ventricular systolic dysfunction, and to select one formulation for further evaluation. During the dose escalation phase, approximately 40 patients were randomized 1:1:1:1 to placebo or one of three different oral formulations of omecamtiv mecarbil in each of two ascending dose escalation cohorts to enable selection of one of these oral formulations for the expansion phase of the trial. Omecamtiv mecarbil is a novel cardiac myosin activator and is the subject of collaboration between Cytokinetics and Amgen. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTK:US $4.89 USD 0.00

CYTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.19 USD -0.01
CTI BioPharma Corp $2.44 USD +0.01
Curis Inc $1.17 USD +0.02
Exelixis Inc $1.33 USD -0.02
GlaxoSmithKline SAE £12.37 EGP 0.00
View Industry Companies
 

Industry Analysis

CYTK

Industry Average

Valuation CYTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOKINETICS INC, please visit www.cytokinetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.